

Published in final edited form as:

Angew Chem Int Ed Engl. 2014 June 16; 53(25): 6519–6522. doi:10.1002/anie.201403006.

Efficient Synthesis of THP/THF-Containing Macrolides via Palladium-Catalyzed Alkoxy carbonylative Macrolactonizations

Yu Bai, Dexter C. Davis, and Mingji Dai

Department of Chemistry, Purdue University 560 Oval Drive, West Lafayette, IN 47907 (USA),

Homepage: <http://www.chem.purdue.edu/dai/>

Mingji Dai: mjdai@purdue.edu

Abstract

A novel Pd-catalyzed cascade alkoxy carbonylative macrolactonization to construct THP/THF-containing bridged macrolactones in one step from alkendiols is described. Products with various ring sizes and substituents were obtained. Challenging macrolactones involving tertiary alcohols were synthesized smoothly as well. Mechanistically, experimental evidence to support a trans-oxy palladation step has been provided. The method was applied to the synthesis of potent anticancer 9-demethylneopeltolide.

Keywords

Macrolide; Palladium; Carbonylation; Neopeltolide; Macrolactonization

Macrocyclic structural motifs are widely prevalent in many approved drug molecules, natural products and other molecules with important function.^[1] Among them, tetrahydropyran (THP) and tetrahydrofuran (THF)-containing macrolides are a diverse group of natural products with a wide range of biological activity.^[2] For example, neopeltolide (**1**),^[3] lyngbyaloside B (**2**),^[4] and exigulide (**3**)^[5] have shown potent anticancer activity (Figure 1). Neopeltolide also exhibits potent antifungal activity against pathogenic yeast *Candida albicans*. Exiguolide specifically inhibits fertilization of sea urchin gametes.

The core structural skeletons of THP/THF-containing natural macrolides can be represented as generic structure **4** (Figure 1). Various strategies have been developed to prepare such structural motifs. Currently, most of them are synthesized from seco-acid precursors via various macrolactonizations.^[6] Most of the commonly used macrolactonization methods require multiple steps to prepare the corresponding seco-acids including tedious masking and unmasking of the carboxylic acid and/or alcohol, more than stoichiometric amount of reagents to activate the carboxylic acid and/or alcohol, and relatively harsh reaction conditions to promote the macrolactonization. While other methods such as ring-closing metathesis,^[7] macrocyclic Prins-type cyclizations,^[8] dual macrolactonization/pyran-

Correspondence to: Mingji Dai, mjdai@purdue.edu.

Supporting information for this article is available on the WWW under <http://www.angewandte.org> or from the author.

hemiketal formation via acylketene intermediate^[9] and transannular oxa-Michael cyclizations^[10] have been used recently to make several THP-containing macrolides, highly efficient and catalytic methods are still needed. We envisioned the possibility of synthesizing both the THP/THF ring and the macrolactone ring in one step from relatively simple alkendiols (cf. **5**→**4**, Figure 1) by developing Pd-catalyzed alkoxycarbonylative macrolactonizations. Pd-catalyzed alkoxycarboxylation, the venerable Semmelhack reaction, has been widely used to make THP/THF-containing esters as well as small sized lactones.^[11] However, to date, Pd-catalyzed alkoxycarbonylative macrolactonization to form products such as **4** has not been reported. Pd-catalyzed carbonylative macrocyclization has been rarely studied as well.^[12] We were hoping to trap the reactive acyl-palladium species derived from a sequence of Wacker-type oxypalladation and CO migratory insertion by a tethered remote alcohol to afford the desired THP/THF-containing bridged macrolactone. The proposed process requires only a catalytic amount of palladium catalyst. Since olefins are relatively inert and compatible in most of the reaction conditions, tedious masking and unmasking practices could be avoided. In addition, no carboxylic acid synthesis and its further activation are required. We were also hoping that the palladium metal center might serve as a template through coordination to bring the remote nucleophilic alcohol and the electrophilic acyl species into proximity and therefore facilitate the macrolactonization by compensating the entropic disadvantage. Herein, we report a novel Pd-catalyzed cascade alkoxycarbonylative macrolactonization to synthesize various THP/THF-containing bridged macrolactones including 9-demethylnepeltolide (**1a**).

Our exploration started with the commonly used Semmelhack reaction conditions and the Lambert carbonylation conditions.^[13] After investigating several reaction parameters, we found that various THP/THF-containing macrolactones could be obtained using Pd(OAc)₂ (0.1 equiv) as catalyst and CuCl₂ (3.0 equiv) as oxidant under carbon monoxide atmosphere (balloon) in 1,2-dichloroethane (DCE, 0.002 M) at room temperature with slow addition of the starting alkendiols. As the macrolactone ring changes from 13- to 18-membered ring (**7a–h**), there is no significant change in the reaction yield and *cis*-2,6-disubstituted THP-containing macrolactones were produced as the predominant products. The reaction condition is compatible with ketal group (**7g**). Both internal *cis* and *trans* double bonds are tolerated as well (**7j–k**). Notably, *para*- and *meta*-cyclophanes were synthesized in **7l** and **7m**, respectively. A 23-membered macrolactone ring was formed in the case of **7l**, which represents the largest ring size we have explored so far. The structure of *cis*-**7m** was unambiguously assigned by X-ray crystallography.^[14] Epimeric substrates **6n** and **6o** underwent the cascade reaction and gave products **7n** and **7o** in 79% and 61% yield respectively. While *cis*-THP product is slightly favored in the case of **7o** (dr. 2/1), *trans*-THP product dominates in the case of **7n** (dr. 1/3.3). Product **7p** was obtained in 77% yield, surprisingly, with almost no diastereoselectivity. THF-containing macrolactones were formed in good yield as well (**7q–r**) but with poor diastereoselectivity. The reaction tolerates sterically hindered alcohol next to an all-carbon quaternary center (**7q**).

Since the new stereocenter is formed in the oxypalladation step, we wondered the details of this step in our case. *trans*-Oxypalladation has been proposed for the Semmelhack reaction.^[11,15] Recently, elegant studies from several groups^[16] including those of Stoltz,

Hayashi, Wolfe and Henry have shown that, in the Wacker-type reaction, both *cis*- and *trans*-oxypalladation pathways are feasible. Similar phenomena have been observed in the related aminopalladation reactions.^[17] Thus, substrate **8** with a *cis*-double bond was prepared and subjected to the carbonylative macrolactonization conditions. Products **9** and **10** were obtained in 51% yield with 8.3/1 diastereoselectivity favoring *cis* product **9** (Scheme 1). The relative configuration of **9** was assigned based on NOE studies. The stereochemical outcome at the α -carbon (asterisked) of **9** supports a *trans*-oxypalladation process via a chair-like transition state (cf. **8**→**A**→**B**→**9**). The minor product was tentatively assigned as **10** based on transition state **C**, which is less favored than **A** due to strong steric repulsions. Since CuCl₂ was used as oxidant, at this stage, we cannot exclude the formation of acyl chlorides for the macrolactonization.^[13,18]

We then wondered whether the Pd-catalyzed alkoxycarbonylative macrolactonization would provide challenging tertiary macrolactones, which are common structural feature of many natural products such as lyngbyaloside B (**2**). Macrolactonization involving the OH group of a tertiary alcohol presents a great synthetic challenge and has not been well studied.^[9,19] We evaluated tertiary alcohol substrates **11a–d**. All of them underwent the cascade cyclization smoothly and gave the desired tertiary macrolactones in good yield and diastereoselectivity.

We then tested the effectiveness of the Pd-catalyzed alkoxycarbonylative macrolactonization for synthesizing 9-demethylnepeltolide,^[20] a simplified nepeltolide^[8a–b,21] analog but with similar inhibitory activity against P388 murine leukemia cells (IC₅₀ = 0.813 nM). In order to evaluate the Pd-catalyzed alkoxycarbonylative macrolactonization in different stereo-settings and generate stereoisomers of 9-demethylnepeltolide, we prepared epimers **13a** and **13b** (see Supporting Information for their synthesis). Both **13a** and **13b** underwent the desired cyclization and products **14a** and **14b** were produced, respectively, in good yield and excellent *cis*-selectivity. Compound **14b** was then converted to 9-demethylnepeltolide (**1a**) uneventfully through a sequence of ketal removal, reduction and Mitsunobu reaction with the known acid **16**^[22] (see Supporting Information for its structure).

In summary, we have developed an efficient Pd-catalyzed cascade alkoxycarbonylative macrolactonization to construct THP/THF-containing macrolactones with different ring sizes and substituents. Challenging macrolactones involving tertiary alcohols were synthesized efficiently as well. Mechanistically, experiments have been conducted to support a Wacker-type *trans*-oxypalladation step. The application of this method was demonstrated in the synthesis of 9-demethylnepeltolide.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

We thank the Xia group at Purdue University for mass spectrometric assistance, the NYU Molecular Design Institute for the purchase of the Bruker SMART APEXII Diffractometer, and Dr. Chunhua Hu for his assistance with data collection and structure determination. Financial support from the Purdue University, Purdue Center for Cancer Research and the American Cancer Society, is gratefully acknowledged. Y. Bai thanks the Purdue Research Foundation for a research assistantship and D. Davis thanks the H.C. Brown Funds for a summer research support.

M. Dai is a recipient of the 2013 Showalter Research Trust Award and 2013 ORAU Ralph E. Powe Junior Faculty Enhancement Award.

References

1. a) Driggers EM, Hale SP, Lee J. *Nat Rev Drug Discov.* 2008; 7:608–624. [PubMed: 18591981] b) Kopp F, Stratton CF, Akella LB, Tan DS. *Nat Chem Bio.* 2012; 8:358–365. [PubMed: 22406518]
2. Lorente A, Lamariano-Merketegi J, Albericio F, Álvarez M. *Chem Rev.* 2013; 113:4567–4610. [PubMed: 23506053]
3. Wright AE, Botelho JC, Guzmán E, Harmody D, Linley P, McCarthy PJ, Pitts TP, Pomponi SA, Reed JK. *J Nat Prod.* 2007; 70:412–416. [PubMed: 17309301]
4. Luesch H, Yoshida WY, Harrigan GG, Doom JP, Moore RE, Paul VJ. *J Nat Prod.* 2002; 65:1945–1948. [PubMed: 12502348]
5. a) Ohta S, Uy MM, Yanai M, Ohta E, Hirata T, Ikegami S. *Tetrahedron Lett.* 2006; 47:1957–1960. b) Crane EA, Zabawa TP, Farmer RL, Scheidt KA. *Angew Chem.* 2011; 123:9278–9281. *Angew Chem Int Ed.* 2011; 50:9112–9115. c) Fuwa H, Suzuki T, Kubo H, Yamori T, Sasaki M. *Chem Eur J.* 2011; 17:2678–2688. [PubMed: 21264972]
6. For reviews: Parenty A, Moreau X, Niel G, Campagne JM. *Chem Rev.* 2013; 113:PR1-PR40. [PubMed: 23005342] Parenty A, Moreau X, Campagne JM. *Chem Rev.* 2006; 106:911–939. [PubMed: 16522013]
7. a) Grubbs, RH. *Handbook of Metathesis.* Vol. 2. Wiley-VCH; Weinheim, Germany: 2003. b) Cossy, J.; Arseniyadis, S.; Meyer, C. *Metathesis in Natural Product Synthesis.* Wiley-VCH; Weinheim, Germany: 2010.
8. a) Custar DW, Zabawa TP, Scheidt KA. *J Am Chem Soc.* 2008; 130:804–805. [PubMed: 18161979] b) Woo SK, Kwon MS, Lee E. *Angew Chem.* 2008; 120:3286–3288. *Angew Chem Int Ed.* 2008; 47:3242–3244. c) Wender PA, DeChristopher BA, Schrier AJ. *J Am Chem Soc.* 2008; 130:6658–6659. [PubMed: 18452292] d) Bahnck KB, Rychnovsky SD. *J Am Chem Soc.* 2008; 130:13177–13181. [PubMed: 18767844]
9. a) Hoyer TR, Danielson ME, May AE, Zhao H. *Angew Chem.* 2008; 120:9889–9892. *Angew Chem Int Ed.* 2008; 47:9743–9746. b) Hoyer TR, Danielson ME, May AE, Zhao H. *J Org Chem.* 2010; 75:7052–7060. [PubMed: 20932014]
10. a) Hilli F, White JM, Rizzacasa MA. *Org Lett.* 2004; 6:1289–1292. [PubMed: 15070319] b) Kanematsu M, Yoshida M, Shishido K. *Angew Chem.* 2011; 123:2666–2668. *Angew Chem Int Ed.* 2011; 50:2618–2620.
11. Semmelhack MF, Bodurow CJ. *J Am Chem Soc.* 1984; 106:1496–1498. Semmelhack MF, Kim C, Zhang N, Sanner BM, Meier M. *Pure Appl Chem.* 1990; 62:2035–2040. Li Z, Gao Y, Jiao Z, Wu N, Wang DZ, Yang Z. *Org Lett.* 2008; 10:5163–5166. [PubMed: 18922007] . For examples of synthetic applications: Carpenter J, Northrup AB, Chung D, Wiener JJM, Kim S-G, MacMillan DWC. *Angew Chem.* 2008; 120:3624–3628. *Angew Chem Int Ed.* 2008; 47:3568–3572. Yang Z, Xie X, Jing P, Zhao G, Zheng J, Zhao C, She X. *Org Biomol Chem.* 2011; 9:984–986. [PubMed: 21152612] Xiao Q, Ren WW, Chen ZX, Sun TW, Li Y, Ye QD, Gong JX, Meng FK, You L, Liu YF, Zhao MZ, Xu LM, Shan ZH, Shi Y, Tang YF, Chen JH, Yang Z. *Angew Chem.* 2011; 123:7511–7515. *Angew Chem Int Ed.* 2011; 50:7373–7377.
12. a) Wu X, Neumann H, Beller M. *Chem Rev.* 2013; 113:1–35. [PubMed: 23039127] b) Lu SM, Alper H. *J Am Chem Soc.* 2005; 127:14776–14784. [PubMed: 16231932] c) Lu SM, Alper H. *Chem Eur J.* 2007; 13:5908–5916. [PubMed: 17444546] d) Lu SM, Alper H. *J Am Chem Soc.* 2008; 130:6451–6455. [PubMed: 18444651] e) Lenoble G, Urrutigoity M, Kalck P. *Tetrahedron Lett.* 2001; 42:3697–3700. f) Knight JC, Prabakaran R, Ward BD, Amoroso AJ, Edwards PG, Kariuki BM. *Dalton Trans.* 2010; 39:10031–10033. [PubMed: 20877912] g) Setoh M, Yamada O, Ogasawara K. *Heterocycles.* 1995; 40:539–542. h) Yoneda E, Zhang SW, Onitsuka K, Takahashi S. *Tetrahedron Lett.* 2001; 42:5459–5461. i) Takahashi T, Kusaka S-i, Doi T, Sunazuka T, Omura S. *Angew Chem.* 2003; 115:5388–5392. *Angew Chem Int Ed.* 2003; 42:5230–5234.
13. a) Cernak TA, Lambert TH. *J Am Chem Soc.* 2009; 131:3124–3125. [PubMed: 19209934] b) Ambrosini LA, Cernak TA, Lambert TH. *Synthesis.* 2010:870–881. c) Ambrosini LA, Cernak TA, Lambert TH. *Tetrahedron.* 2010; 66:4882–4887.

14. CCDC 985926 contains the supplementary crystallographic data for compound *cis*-7m.
15. Stille JK, Divakaruni R. *J Organomet Chem.* 1979; 169:239–248.. For examples of trans-oxy-palladation in the Wacker reaction, see: Bäckvall JE, Akermark B, Ljunggren SO. *J Am Chem Soc.* 1979; 101:2411–2416. Majima T, Kurosawa H. *J Chem Soc Chem Commun.* 1977:610–611.
16. a) Trend RM, Ramtohul YK, Stoltz BM. *J Am Chem Soc.* 2005; 127:17778–17788. [PubMed: 16351107] b) Uozumi Y, Kato K, Hayashi T. *J Am Chem Soc.* 1997; 119:5063–5064. c) Hayashi T, Yamasaki K, Mimura M, Uozumi Y. *J Am Chem Soc.* 2004; 126:3036–3037. [PubMed: 15012118] d) Hay MB, Hardin AR, Wolfe JP. *J Org Chem.* 2005; 70:3099–3107. [PubMed: 15822970] e) Francis JW, Henry PM. *J Mol Catal A: Chem.* 1996; 112:317–326.
17. a) Liu G, Stahl SS. *J Am Chem Soc.* 2007; 129:6328–6335. [PubMed: 17439217] b) Bäckvall JE. *Acc Chem Res.* 1983; 16:335–342.
18. Quesnel JS, Arndtsen BA. *J Am Chem Soc.* 2013; 135:16841–16844. [PubMed: 24144068]
19. a) Masamune S, Hayase Y, Schilling W, Chan W, Bates GS. *J Am Chem Soc.* 1977; 99:6756–6758. [PubMed: 893906] b) Booth PM, Fox CM, Ley SV. *J Chem Soc Perkin Trans.* 1987; 1:121–129. c) Clyne DS, Weiler L. *Tetrahedron.* 1999; 55:13659–13682. d) ElMarrouni A, Lebeuf R, Gebauer J, Heras M, Arseniyadis S, Cossy J. *Org Lett.* 2012; 14:314–317. [PubMed: 22149647]
20. For the synthesis and biological evaluation of 9-demethylnepeltolide: Fuwa H, Saito A, Naito S, Konoki K, Yotsu-Yamashita M, Sasaki M. *Chem Eur J.* 2009; 15:12807–12818. [PubMed: 19882704]
21. For total syntheses of nepeltolide: references 8a and 8b, and Youngsaye W, Lowe JT, Pohlki F, Ralifo P, Panek JS. *Angew Chem.* 2007; 119:9371–9374. *Angew Chem Int Ed.* 2007; 46:9211–9214. Paterson I, Miller NA. *Chem Commun.* 2008:4708–4710. Fuwa H, Naito S, Goto T, Sasaki M. *Angew Chem.* 2008; 120:4815–4817. *Angew Chem Int Ed.* 2008; 47:4737–4739. Ulanovskaya OA, Janjic J, Suzuki M, Sabharwal SS, Schumacker PT, Kron SJ, Kozmin SA. *Nat Chem Biol.* 2008; 4:418–424. [PubMed: 18516048] Guinchard X, Roulland E. *Org Lett.* 2009; 11:4700–4703. [PubMed: 19775106] Fuwa H, Saito A, Sasaki M. *Angew Chem.* 2010; 122:3105–3108. *Angew Chem Int Ed.* 2010; 49:3041–3044. Ghosh AK, Shurrush KA, Dawson ZL. *Org Biomol Chem.* 2013; 11:7768–7777. [PubMed: 24121457] . For formal synthesis: Vintonyak VV, Maier ME. *Org Lett.* 2008; 10:1239–1242. [PubMed: 18302399] Kartika R, Gruffi TR, Taylor RE. *Org Lett.* 2008; 10:5047–5050. [PubMed: 18855401] Tu W, Floreancig PE. *Angew Chem.* 2009; 121:4637–4641. *Angew Chem Int Ed.* 2009; 48:4567–4571. Kim H, Park Y, Hong J. *Angew Chem.* 2009; 121:7713–7717. *Angew Chem Int Ed.* 2009; 48:7577–7581. Yadav JS, Krishana GG, Kumar SN. *Tetrahedron.* 2010; 66:480–487. Martinez-Solorio D, Jennings MP. *J Org Chem.* 2010; 75:4095–4104. [PubMed: 20499942] Yang Z, Zhang B, Zhao G, Yang J, Xie X, She X. *Org Lett.* 2011; 13:5916–5919. [PubMed: 21995677] Raghavan S, Samanta PK. *Org Lett.* 2012; 14:2346–2349. [PubMed: 22515229] Sharma GVM, Reddy SV, Ramakrishna KVS. *Org Biomol Chem.* 2012; 10:3689–3695. [PubMed: 22469969] . For analog synthesis: Vintonyak VV, Kunze B, Sasse F, Maier ME. *Chem Eur J.* 2008; 14:11132–11140. [PubMed: 18979467] Custar DW, Zabawa TP, Hines J, Crews CM, Scheidt KA. *J Am Chem Soc.* 2009; 131:12406–12414. [PubMed: 19663512] Cui Y, Tu W, Floreancig PE. *Tetrahedron.* 2010; 66:4867–4873. [PubMed: 20697460] Cui Y, Balachandran R, Day BW, Floreancig PE. *J Org Chem.* 2012; 77:2225–2235. [PubMed: 22329423] Fuwa H, Kawakami M, Noto K, Muto T, Suga Y, Konoki K, Yotsu-Yamashita M, Sasaki M. *Chem Eur J.* 2013; 19:8100–8110. [PubMed: 23606326]
22. Wang Y, Janjic J, Kozmin SA. *J Am Chem Soc.* 2002; 124:13670–13671. [PubMed: 12431085]







Figure 1.
 Selected THP-containing macrolides and our synthetic strategy.



Scheme 1.
A mechanistic study of the oxypalladation step.

**Scheme 2.**


Alkoxy carbonylative macrolactonization of tertiary alcohols.

**Scheme 3.**

Alkoxy carbonylative macrolactonization of **13a** and **13b** and synthesis of 9-demethylneopeltolide (**1a**). Reagents and conditions: a) HCl (0.5 N), MeOH; then HCl (1 N), THF, RT; b) NaBH_4 (3.9 equiv), MeOH, 0 °C, 74% from **14b**; c) PPh_3 (3.8 equiv), DIAD (3.8 equiv), **16** (4.0 equiv), benzene, RT, 56%; DIAD = diisopropyl azodicarboxylate.

Table 1

Substrate scope



[a] Isolated yield with *cis/trans* ratio in parenthesis.